In a patient with peritoneal carcinomatosis from colon cancer who has good performance status (ECOG 0‑1), no unresectable extra‑abdominal disease, and disease amenable to complete cytoreductive surgery (CC‑0/1), what is the role of hyperthermic intraperitoneal chemotherapy (HIPEC)?

HIPEC Should NOT Be Routinely Added to Cytoreductive Surgery for Colorectal Peritoneal Carcinomatosis

Based on the highest-quality evidence from the PRODIGE 7 trial, HIPEC with oxaliplatin should not be added to cytoreductive surgery (CRS) for colorectal peritoneal carcinomatosis, as it provides no survival benefit and increases late complications. However, complete cytoreductive surgery alone remains a potentially curative option for carefully selected patients at high-volume centers.

Key Evidence Against Routine HIPEC Use

The 2023 ESMO and ASCO guidelines both prioritize the PRODIGE 7 phase III randomized controlled trial, which definitively showed 1:

• No overall survival benefit: HR 1.00 (95% CI 0.63-1.58) when adding oxaliplatin-based HIPEC to CRS 2
• No relapse-free survival benefit: HR 0.91 (95% CI 0.71-1.15) 2
• Increased late complications: 1.69-fold higher rate of grade 3+ adverse events at 60 days post-operatively (RR 1.69; 95% CI 1.03-2.77) 2

Therefore, HIPEC cannot be recommended as standard of care for colorectal peritoneal metastases 1.

The Role of Cytoreductive Surgery Alone

Despite HIPEC not adding benefit, complete cytoreductive surgery (CRS) itself remains valuable for appropriately selected patients 2:

• 15% of patients remained disease-free at 5 years after CRS in PRODIGE 7, indicating CRS can be curative in select cases 2
• Complete macroscopic cytoreduction (CC-0/1) is the critical determinant of long-term survival, not the addition of HIPEC 2
• 91% achieved complete cytoreduction in PRODIGE 7, attributed to treatment at experienced high-volume centers 2

Patient Selection Criteria for CRS

CRS should only be considered when ALL of the following criteria are met 1, 2:

• Limited peritoneal disease amenable to complete cytoreduction (CC-0/1 resection achievable)
• No unresectable extra-abdominal metastases (isolated peritoneal disease)
• Good performance status (ECOG 0-1)
• Treatment at specialized high-volume centers with substantial experience in peritoneal surface malignancies
• Multidisciplinary team evaluation including medical oncology, surgical oncology, radiology, and pathology 2

Critical Pitfalls to Avoid

Do not offer CRS/HIPEC outside specialized centers: The relatively high morbidity (20% major complications) and mortality (up to 8% treatment-related mortality in older studies) requires substantial institutional experience 2, 3. Patients with high peritoneal cancer index scores or extensive disease have median survival of only 1.29 years even with aggressive treatment 4.

Completeness of cytoreduction is paramount: Patients with extensive residual disease after attempted cytoreduction have dismal outcomes (70% mortality within 21.6 months with extensive residual disease) 2. If complete cytoreduction cannot be achieved, CRS should not be performed.

Alternative HIPEC Regimens Under Investigation

While oxaliplatin-based HIPEC (30-minute protocol used in PRODIGE 7) showed no benefit 2:

• Mitomycin-C based protocols are still being investigated, with the Dutch protocol (35 mg/m², 90 minutes, three fractions) showing weak positive consensus among experts 5
• Longer-duration HIPEC protocols may produce different results, though PRODIGE 7 authors speculate mitomycin-C would not have changed outcomes 2
• Guidelines will be updated if future studies with alternative regimens demonstrate benefit 2

Shared Decision-Making Considerations

When discussing CRS (without HIPEC) with eligible patients, address 2:

• Potential for cure exists: 15% remain disease-free at 5 years, but 85% will experience recurrence
• Significant morbidity: 20% major complication rate, prolonged recovery
• Quality of life impact: Extensive surgery requiring 8-14 hours operative time 6
• Alternative of systemic chemotherapy alone: Modern regimens provide median survival of approximately 20 months for unresectable disease 7, 8

Treatment Algorithm

1. Confirm isolated peritoneal disease with no unresectable extra-abdominal metastases
2. Refer to high-volume specialized center for multidisciplinary evaluation
3. Assess resectability via imaging ± diagnostic laparoscopy
4. If complete cytoreduction achievable: Proceed with CRS alone (without HIPEC)
5. If incomplete cytoreduction likely: Offer systemic chemotherapy; consider clinical trial enrollment 4
6. Perioperative systemic chemotherapy: Consider FOLFOX-based regimens before and/or after CRS 1